FDA Approves First Treatment for Eosinophilic Esophagitis

In May, the U.S. Food and Drug Administration approved dupilumab (Dupixent) as a treatment for eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds). Today’s action marks the first FDA approval of a treatment for EoE. Dupilumab, originally approved by the FDA […]
Source: ENT Today - Category: ENT & OMF Authors: Tags: Laryngology Online Exclusives Practice Focus dupilumab eosinophilic esophagitis patient care Source Type: research